Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACKLE: AZD7442 for outpatient treatment of mild to moderate COVID-19
jRCT2031200368Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AZD7442 with Placebo (2 arms). Primary endpoint: Composite of severe COVID-19 or death from any cause through Day 29. Started Jan 2021; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031200368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200368.